Your Cart is Empty
Dementia is one of the most pressing health challenges of our time. Tens of millions of people worldwide are living with it, and as populations age, that number is expected to climb. Growing older increases the risk not only of dementia, but also of a range of other problems — from chronic inflammation to reduced organ function.
Now, an intriguing line of research suggests that something surprisingly simple may help: the shingles vaccine.
Recent findings from several countries indicate that people who receive the shingles vaccine appear to have about a 20% lower risk of developing dementia over the following years. While the idea might sound unexpected, the data are steadily accumulating.
The Link Between Shingles and the Brain
Shingles is caused by the same virus that produces chickenpox. After someone recovers from chickenpox, the virus doesn’t disappear. Instead, it lies dormant in nerve tissue and can reactivate decades later as shingles — a painful rash that can also cause lingering nerve pain.
Older shingles vaccines used a weakened live version of the virus. Today, most countries use a newer vaccine known as Shingrix, which does not contain live virus. Instead, it includes small fragments of viral proteins that train the immune system to recognize and fight the real virus if it reappears.
Public health agencies in many regions recommend shingles vaccination for adults typically between 65 and 80 years old, though eligibility ages vary slightly by country. These age-based rollout policies have created a valuable opportunity for scientists. Because eligibility is often determined by birth year, researchers can compare people just above and just below the age cutoff. This creates what scientists call a “natural experiment.”
In simple terms, when two groups of people are nearly identical in age — differing only by a few months — but one group becomes eligible for vaccination and the other does not, it allows researchers to observe what happens next. If health outcomes diverge between the groups, vaccination may be playing a role.
What the Research Shows
Dr. Pascal Geldsetzer of Stanford University has been studying this question across multiple countries. Using large healthcare datasets from Australia, New Zealand, Wales, and most recently Ontario, Canada, his team examined records from hundreds of thousands of older adults.
The Ontario analysis alone included more than 460,000 people. Across all regions studied, a consistent pattern emerged: individuals eligible for shingles vaccination were less likely to develop dementia or mild cognitive impairment in the years that followed.
According to Dr. Geldsetzer, the best estimate so far is that shingles vaccination may prevent about one in five new dementia cases over a seven-year period. That’s a meaningful reduction, especially given the global burden of the disease.
Benefits Beyond Dementia?
The story may not end with brain health.
Another study, published earlier this year in The Journals of Gerontology, explored whether shingles vaccination might influence overall biological aging. Researchers assessed nearly 4,000 adults over age 70 using a “healthy aging” score. This score considered several indicators, including inflammation levels and biological markers associated with aging at the cellular level.
Those who had previously received the shingles vaccine showed lower levels of inflammation and scored better overall on measures of healthy aging.
While these findings don’t prove cause and effect, they add weight to the possibility that the vaccine’s benefits extend beyond preventing a painful rash.
Why Might This Happen?
Scientists are still working to understand the mechanism behind these observations. There are two leading theories.
One possibility is that the chickenpox virus, even while dormant, may cause subtle ongoing harm in the body — perhaps through low-level reactivation or chronic immune stimulation. By strengthening the immune response against the virus, vaccination could reduce that hidden damage.
Another explanation is broader immune enhancement. Vaccines don’t just target one pathogen; they can also stimulate the immune system more generally. The shingles vaccine might improve immune function in ways that protect against processes involved in dementia, such as inflammation or vascular damage.
If this second theory is correct, it raises an even bigger question: might other vaccines offer similar protective effects?
Important Unknowns
Despite the promising results, several key questions remain unanswered.
Researchers do not yet know:
Although serious side effects from the shingles vaccine are rare, especially in older adults, more evidence would be needed before expanding recommendations to younger age groups.
In other words, while the data are encouraging, they are not yet definitive enough to reshape vaccination policy solely around dementia prevention.
What Happens Next?
To move from strong observational evidence to firmer conclusions, randomized clinical trials will likely be necessary. These studies, which assign participants to vaccination or placebo groups under controlled conditions, could clarify both the size of the benefit and the biological mechanism behind it.
Dr. Geldsetzer has expressed interest in pursuing such trials. In the meantime, he considers the current evidence compelling enough to influence his own decision. He has received the vaccine himself, noting that researchers should practice what they recommend.
A Practical Takeaway
For now, the shingles vaccine remains primarily a tool to prevent shingles and its complications — which alone is reason enough for many older adults to consider it.
However, the emerging research offers an intriguing possibility: protecting yourself against shingles might also support long-term brain health.
As scientists continue to investigate, one thing is clear — the immune system and the brain are more interconnected than once believed. And sometimes, advances in one area of medicine unexpectedly ripple into another.
If future research confirms these findings, a simple vaccination could become part of a broader strategy to promote healthy aging — not just free from rash, but free from cognitive decline as well.
